Cosette Pharmaceuticals Inc., a specialty pharmaceutical company and backed by Avista Capital Partners, has acquired the US sales and distribution rights to eight branded commercial products from Daiichi Sankyo Co., a Japanese pharmaceutical company.
The deal adds eight prescription products concentrated on cardiovascular indications to Cosette’s portfolio of over 45 commercial products. The products include Benicar, Benicar HCT, Welchol tablets, Welchol oral suspension, Azor, Tribenzor, Effient, Evoxac.
“This transformative acquisition represents a significant expansion and diversification of Cosette’s portfolio and business,” said Apurva Saraf, Cosette’s president and CEO. “We look forward to build on this transaction and successfully acquire and integrate important product portfolios in the future, and to continue to make these critical medications available for patients and prescribers.”
Morgan Lewis & Bockius LLP served as legal counsel and BofA Securities served as exclusive financial advisor to Cosette Pharmaceuticals. Goldman Sachs & Co. LLC served as exclusive financial advisor to Daiichi Sankyo.